

Maria Eriksson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8377282/publications.pdf>

Version: 2024-02-01

177
papers

6,031
citations

76196

40
h-index

95083

68
g-index

187
all docs

187
docs citations

187
times ranked

9172
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease. Cellular and Molecular Neurobiology, 2023, 43, 797-811.	1.7	19
2	Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program. Alzheimer's and Dementia, 2023, 19, 999-1008.	0.4	9
3	Validating a model for medication-related dental outcomes in older people. Oral Diseases, 2022, 28, 1697-1704.	1.5	1
4	Body mass index and Mini Nutritional Assessment-Short Form as predictors of in-geriatric hospital mortality in older adults with COVID-19. Clinical Nutrition, 2022, 41, 2973-2979.	2.3	23
5	Periodontal conditions and incident dementia: A nationwide Swedish cohort study. Journal of Periodontology, 2022, 93, 1378-1386.	1.7	5
6	Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia. Journal of Alzheimer's Disease, 2022, 86, 245-257.	1.2	4
7	Response to Letter to the Editor: Comment on "Body mass index and Mini Nutritional Assessment-Short Form as predictors of in-geriatric hospital mortality in older adults with COVID-19" (by Caf� Balc�, MD, Hacettepe University Faculty of Medicine Department of Internal Medicine Division) Tj ETQq1 1 0.784314 rgB	2.3	1
8	Development of an Electronic Frailty Index for Hospitalized Older Adults in Sweden. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2311-2319.	1.7	11
9	COVID-19 pandemic and mortality in nursing homes across USA and Europe up to October 2021. European Geriatric Medicine, 2022, 13, 705-709.	1.2	25
10	Fast Alpha Activity in EEG of Patients With Alzheimer's Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Bodelivery of Nerve Growth Factor. Frontiers in Aging Neuroscience, 2022, 14, 756687.	1.7	3
11	Changes in dementia diagnoses in Sweden during the COVID-19 pandemic. BMC Geriatrics, 2022, 22, 365.	1.1	10
12	Behavioral and Psychological Symptoms of Dementia in Different Dementia Disorders: A Large-Scale Study of 10,000 Individuals. Journal of Alzheimer's Disease, 2022, 87, 1307-1318.	1.2	22
13	Conversion Between the Mini-Mental State Examination and the Montreal Cognitive Assessment for Patients With Different Forms of Dementia. Journal of the American Medical Directors Association, 2022, 23, 1986-1989.e1.	1.2	8
14	FC081: Cholinesterase Inhibitors and Kidney Function Decline in Patients with Alzheimer's Dementia. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
15	Discontinued dental care attendance among people with dementia: A register-based longitudinal study. Gerodontology, 2021, 38, 57-65.	0.8	4
16	Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study. Journal of Internal Medicine, 2021, 289, 508-522.	2.7	9
17	Satisfaction with Stroke Care Among Patients with Alzheimer's and Other Dementias: A Swedish Register-Based Study. Journal of Alzheimer's Disease, 2021, 79, 905-916.	1.2	2
18	Statins, Risk of Death and Ischemic Stroke in Patients with Dementia: A Registry-Based Observational Cohort Study. Current Alzheimer Research, 2021, 17, 881-892.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Subgingival microbiota in a population with and without cognitive dysfunction. <i>Journal of Oral Microbiology</i> , 2021, 13, 1854552.	1.2	24
20	A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1331, 167-191.	0.8	10
21	Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. <i>Neurology</i> , 2021, 96, e2220-e2230.	1.5	75
22	Acute kidney injury and mortality risk in older adults with COVID-19. <i>Journal of Nephrology</i> , 2021, 34, 295-304.	0.9	23
23	Biting the Bullet: Firearm Ownership in Persons with Dementia. A Registry-Based Observational Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 179-188.	1.2	2
24	Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults. <i>Neurology</i> , 2021, 96, .	1.5	50
25	Cerebrospinal Fluid Inflammatory Markers in Alzheimer's Disease: Influence of Comorbidities. <i>Current Alzheimer Research</i> , 2021, 18, 157-170.	0.7	3
26	Changes in Drug Prescribing Practices Are Associated With Improved Outcomes in Patients With Dementia in Sweden: Experience from the Swedish Dementia Registry 2008-2017. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1477-1483.e3.	1.2	3
27	Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. <i>Cells</i> , 2021, 10, 1871.	1.8	12
28	Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 714186.	1.7	9
29	CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 704583.	1.7	14
30	Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1565-1573.e4.	1.2	9
31	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial-The OmegAD Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1291-1301.	1.2	10
32	Gene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 179, 219-229.	1.0	1
33	Amyloid-Beta Peptides and Activated Astroglia Impairs Proliferation of Nerve Growth Factor Releasing Cells In Vitro: Implication for Encapsulated Cell Biodelivery-Mediated AD Therapy. <i>Cells</i> , 2021, 10, 2834.	1.8	2
34	Author Response: Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. <i>Neurology</i> , 2021, 97, 965-965.	1.5	1
35	The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 197.	3.0	15
36	Considerations for drug delivery utilizing encapsulated cells: Factors for optimal cell behavior. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
37	Clinical characteristics and treatments in patients with chronic kidney disease and dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
38	Do Acetylcholinesterase Inhibitors Prevent or Delay Psychotropic Prescribing in People With Dementia? Analyses of the Swedish Dementia Registry. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 108-117.	0.6	17
39	Costs of Inpatient Rehabilitation for Ischemic Stroke in Patients with Dementia: A Cohort Swedish Register-Based Study. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 967-979.	1.2	4
40	Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1013-1021.	1.2	9
41	Survival time tool to guide care planning in people with dementia. <i>Neurology</i> , 2020, 94, e538-e548.	1.5	37
42	Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ~1/4 130,000 Swedish Subjects over 14 Years. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1581-1594.	1.2	11
43	Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1555-1559.e2.	1.2	141
44	Xerogenic medications as a predictor for dental health intervention in people with dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e039181.	0.4	0
45	Dementia diagnosis affects pharmacological management of diabetes mellitus: A matched analysis of ~1/4 420,000 patients from the Swedish registries. <i>Alzheimer's and Dementia</i> , 2020, 16, e039772.	0.4	0
46	Population attributable fraction of dementia risk in individuals with reduced kidney function. <i>Alzheimer's and Dementia</i> , 2020, 16, e041994.	0.4	0
47	Treatment implementation leads to improved outcomes in patients with dementia in Sweden from 2008-2017: Experience from the Swedish Dementia Registry. <i>Alzheimer's and Dementia</i> , 2020, 16, e042061.	0.4	0
48	Long-term treatment with cholinesterase inhibitors in Alzheimer's disease is associated with modest but persisting benefits on cognition and reduced mortality. <i>Alzheimer's and Dementia</i> , 2020, 16, e042880.	0.4	0
49	Encapsulated cell biodelivery of NGF (ECB-NGF) for AD therapy has implications from astroglial activation and amyloid-beta toxicity. <i>Alzheimer's and Dementia</i> , 2020, 16, e045104.	0.4	1
50	Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 891-902.	1.2	22
51	Xerogenic Medications as a Predictor for Dental Health Intervention in People with Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1263-1271.	1.2	2
52	The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 51.	3.0	41
53	Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000833.	1.2	20
54	The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment. <i>BMC Geriatrics</i> , 2020, 20, 93.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Controlling for selective dropout in longitudinal dementia data: Application to the SveDem registry. <i>Alzheimer's and Dementia</i> , 2020, 16, 789-796.	0.4	16
56	Cholinergic white matter pathways make a stronger contribution to attention and memory in normal aging than cerebrovascular health and nucleus basalis of Meynert. <i>NeuroImage</i> , 2020, 211, 116607.	2.1	59
57	Satisfaction with stroke care among dementia patients with stroke: A Swedish register study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043116.	0.4	0
58	Identification of amino acid residues of nerve growth factor important for neurite outgrowth in human dorsal root ganglion neurons. <i>European Journal of Neuroscience</i> , 2019, 50, 3487-3501.	1.2	6
59	CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 239.	1.4	15
60	Basic Diagnostic Work-Up Is More Complete in Rural than in Urban Areas for Patients with Dementia: Results of a Swedish Dementia Registry Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 455-462.	1.2	7
61	Antipsychotic Treatment Associated With Increased Mortality Risk in Patients With Dementia. A Registry-Based Observational Cohort Study. <i>Journal of the American Medical Association</i> , 2019, 20, 323-329.e2.	1.2	25
62	Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegaAD Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 189-197.	1.2	44
63	Innovative Therapy for Alzheimer's Disease-With Focus on Bidelivery of NGF. <i>Frontiers in Neuroscience</i> , 2019, 13, 38.	1.4	103
64	Multimorbidity and functional impairment—bidirectional interplay, synergistic effects and common pathways. <i>Journal of Internal Medicine</i> , 2019, 285, 255-271.	2.7	210
65	The caregiving phenomenon and caregiver participation in dementia. <i>Scandinavian Journal of Caring Sciences</i> , 2019, 33, 255-265.	1.0	32
66	Decisions and attitudes regarding participation and proxy in clinical trials among patients with impaired cognitive function. <i>Dementia</i> , 2019, 18, 2049-2061.	1.0	2
67	Mortality and nursing home placement of dementia patients in rural and urban areas: a cohort study from the Swedish Dementia Registry. <i>Scandinavian Journal of Caring Sciences</i> , 2018, 32, 1308-1313.	1.0	6
68	Targeting Alzheimer's disease with gene and cell therapies. <i>Journal of Internal Medicine</i> , 2018, 284, 2-36.	2.7	42
69	The Impact of Antipsychotic Drugs on Long-term Care, Nursing Home Admission, and Death in Dementia Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1396-1402.	1.7	16
70	Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1119-1128.	1.2	46
71	Prescription Changes During Geriatric Care Episodes: A Trend Analysis Conducted in Sweden. <i>Drugs and Aging</i> , 2018, 35, 243-248.	1.3	4
72	Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia. <i>Alzheimer's and Dementia</i> , 2018, 14, 944-951.	0.4	37

#	ARTICLE	IF	CITATIONS
73	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018, 14, 895-901.	0.4	8
74	Dental care utilization in patients with different types of dementia: A longitudinal nationwide study of 58,037 individuals. <i>Alzheimer's and Dementia</i> , 2018, 14, 10-19.	0.4	53
75	Prestroke Mobility and Dementia as Predictors of Stroke Outcomes in Patients Over 65 Years of Age: A Cohort Study From The Swedish Dementia and Stroke Registries. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 154-161.	1.2	25
76	P3603: SEX DIFFERENCES IN ACUTE STROKE CARE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1358.	0.4	0
77	Stroke as a Cause of Death in Death Certificates of Patients with Dementia: A Cohort Study from the Swedish Dementia Registry. <i>Current Alzheimer Research</i> , 2018, 15, 1322-1330.	0.7	12
78	P1001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI. <i>Alzheimer's and Dementia</i> , 2018, 14, P261.	0.4	0
79	Association between periodontitis and risk of Alzheimer's disease, mild cognitive impairment and subjective cognitive decline: A case-control study. <i>Journal of Clinical Periodontology</i> , 2018, 45, 1287-1298.	2.3	85
80	Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. <i>Journal of Internal Medicine</i> , 2018, 284, 620-642.	2.7	30
81	Acute Stroke Care in Dementia: A Cohort Study from the Swedish Dementia and Stroke Registries. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 185-194.	1.2	12
82	The Effect of Xerostomic Medication on Oral Health in Persons With Dementia. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 1080-1085.e2.	1.2	13
83	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45.	3.0	11
84	Anticholinergic Burden and Risk of Stroke and Death in People with Different Types of Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 589-596.	1.2	31
85	No Significant Difference in Cognitive Decline and Mortality between Parkinson's Disease Dementia and Dementia with Lewy Bodies: Naturalistic Longitudinal Data from the Swedish Dementia Registry. <i>Journal of Parkinson's Disease</i> , 2018, 8, 553-561.	1.5	10
86	Cerebrospinal fluid from Alzheimer patients affects cell-mediated nerve growth factor production and cell survival in vitro. <i>Experimental Cell Research</i> , 2018, 371, 175-184.	1.2	11
87	Differences in diagnostic process, treatment and social Support for Alzheimer's dementia between primary and specialist care: results from the Swedish Dementia Registry. <i>Age and Ageing</i> , 2017, 46, 314-319.	0.7	18
88	Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151.	0.6	12
89	Management of acute ischaemic stroke in patients with dementia. <i>Journal of Internal Medicine</i> , 2017, 281, 348-364.	2.7	37
90	The effects of different familial Alzheimer's disease mutations on APP processing in vivo. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 9.	3.0	32

#	ARTICLE	IF	CITATIONS
91	Thrombolysis in acute ischemic stroke in patients with dementia. <i>Neurology</i> , 2017, 89, 1860-1868.	1.5	28
92	DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegaAD study. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 1157-1165.	2.2	46
93	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. <i>NeuroImage: Clinical</i> , 2017, 16, 418-428.	1.4	23
94	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017, 59, 1-9.	1.5	84
95	Overall and domain-specific life satisfaction when living with familial Alzheimer's disease risk: A quantitative approach. <i>Australian Journal of Cancer Nursing</i> , 2017, 19, 452-458.	0.8	2
96	Do adapted vignettes improve medical decision-making capacity for individuals with Alzheimer's disease?. <i>Scandinavian Journal of Psychology</i> , 2017, 58, 497-503.	0.8	7
97	Big data and data repurposing - using existing data to answer new questions in vascular dementia research. <i>BMC Neurology</i> , 2017, 17, 72.	0.8	24
98	Diabetes in a Large Dementia Cohort: Clinical Characteristics and Treatment From the Swedish Dementia Registry. <i>Diabetes Care</i> , 2017, 40, 1159-1166.	4.3	29
99	Management of Acute Myocardial Infarction in Patients With Dementia: Data From SveDem, the Swedish Dementia Registry. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 19-23.	1.2	27
100	Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 515-519.	1.2	2
101	Living Alone with Alzheimer's Disease: Data from SveDem, the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1265-1272.	1.2	36
102	Quejas cognitivas subjetivas: hacia una identificación precoz de la enfermedad de Alzheimer. <i>Neurología</i> , 2016, 31, 562-571.	0.3	43
103	Diagnosis of Dementia in the Specialist Setting: A Comparison Between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi). <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1341-1351.	1.2	11
104	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 30.	3.0	110
105	Causes of Death According to Death Certificates in Individuals with Dementia: A Cohort from the Swedish Dementia Registry. <i>Journal of the American Geriatrics Society</i> , 2016, 64, e137-e142.	1.3	66
106	Assessment and Reporting of Driving Fitness in Patients with Dementia in Clinical Practice: Data from SveDem, the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 631-638.	1.2	11
107	P270: Longitudinal Investigation of an MRI-Based Alzheimer's Disease Diagnostic Index in Adni. <i>Alzheimer's and Dementia</i> , 2016, 12, P732.	0.4	1
108	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. <i>Brain Topography</i> , 2016, 29, 296-307.	0.8	44

#	ARTICLE	IF	CITATIONS
109	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 430-440.	2.2	32
110	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. <i>Neurobiology of Aging</i> , 2016, 42, 124-131.	1.5	29
111	The meaning of living close to a person with Alzheimer disease. <i>Medicine, Health Care and Philosophy</i> , 2016, 19, 341-349.	0.9	14
112	P1-247: Cardiovascular comorbidities in dementia. , 2015, 11, P448-P448.		1
113	Svedem, the Swedish dementia registry – A tool for improving the quality of diagnostics, treatment and care. <i>Journal of the Neurological Sciences</i> , 2015, 357, e10-e11.	0.3	0
114	Dementia Diagnosis, Treatment, and Care in Specialist Clinics in Two Scandinavian Countries: A Data Comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 229-239.	1.2	22
115	Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 805-812.	1.2	82
116	Cardiovascular Diseases in 1/4 30,000 Patients in the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 949-958.	1.2	35
117	SveDem, the Swedish Dementia Registry – A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice. <i>PLoS ONE</i> , 2015, 10, e0116538.	1.1	124
118	Influence of Allergy on Immunoglobulins and Amyloid- β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 495-505.	1.2	9
119	Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. <i>European Journal of Heart Failure</i> , 2015, 17, 612-619.	2.9	55
120	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 40-48.	1.2	22
121	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1316-1328.	0.4	50
122	Cerebrospinal fluid tau and amyloid- β ₁₋₄₂ in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731.	3.7	152
123	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015, 11, 1470-1479.	0.4	17
124	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 17.	3.0	419
125	Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. <i>Journal of Lipid Research</i> , 2015, 56, 674-681.	2.0	63
126	Heart failure and Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2015, 277, 406-425.	2.7	119

#	ARTICLE	IF	CITATIONS
127	Dementia and Obesity Paradox: Reply to the Letter by Dr Moga etÂal. Journal of the American Medical Directors Association, 2015, 16, 79-81.	1.2	2
128	Resolution of inflammation is altered in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 40.	0.4	208
129	The Use of MRI, CT and Lumbar Puncture in Dementia Diagnostics: Data from the SveDem Registry. Dementia and Geriatric Cognitive Disorders, 2015, 39, 81-91.	0.7	20
130	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
131	Differences in Routine Clinical Practice between Early and Late Onset Alzheimer's Disease: Data from the Swedish Dementia Registry (SveDem). Journal of Alzheimer's Disease, 2014, 41, 411-419.	1.2	26
132	Cognitive predictors of medical decisionâ€making capacity in mild cognitive impairment and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2014, 29, 1304-1311.	1.3	28
133	Subjective Cognitive Impairment Subjects in Our Clinical Practice. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 419-430.	0.6	33
134	Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study. Journal of Alzheimer's Disease, 2014, 42, 823-831.	1.2	61
135	Transfer of omegaâ€ fatty acids across the bloodâ€brain barrier after dietary supplementation with a docosahexaenoic acidâ€rich omegaâ€ fatty acid preparation in patients with <scp>A</scp>lzheimer's disease: the <scp>O</scp>mega<scp>AD</scp> study. Journal of Internal Medicine, 2014, 275, 428-436.	2.7	123
136	Comorbidity profile in dementia with Lewy bodies versus Alzheimerâ€™s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. Alzheimer's Research and Therapy, 2014, 6, 65.	3.0	32
137	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology, 2014, 83, 1945-1953.	1.5	213
138	Galantamine Versus Risperidone Treatment of Neuropsychiatric Symptoms in Patients with Probable Dementia: An Open Randomized Trial. American Journal of Geriatric Psychiatry, 2014, 22, 341-348.	0.6	26
139	Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study. Phytomedicine, 2014, 21, 888-892.	2.3	54
140	Anti-Dementia Drugs and Co-Medication Among Patients with Alzheimerâ€™s Disease. Drugs and Aging, 2014, 31, 215-224.	1.3	40
141	Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2014, 40, 667-678.	1.2	55
142	Body mass index in dementia. European Journal of Clinical Nutrition, 2014, 68, 1204-1209.	1.3	72
143	Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry. Alzheimer's Research and Therapy, 2014, 6, 34.	3.0	29
144	Body-Mass Index and Mortality in Incident Dementia: A Cohort Study on 11,398 Patients From SveDem, the Swedish Dementia Registry. Journal of the American Medical Directors Association, 2014, 15, 447.e1-447.e7.	1.2	49

#	ARTICLE	IF	CITATIONS
145	Response to Bogaiksy's Letter to the Editor. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 951.	0.6	0
146	Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1059-1072.	1.2	71
147	Body Mass Index in Different Dementia Disorders: Results from the Swedish Dementia Quality Registry (SveDem). <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 65-75.	0.6	16
148	Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1393-1402.	1.2	26
149	Mortality Risk after Dementia Diagnosis by Dementia Type and Underlying Factors: A Cohort of 15,209 Patients based on the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 467-477.	1.2	129
150	P3-288: DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE IN SPECIALIST UNITS COMPARED TO PRIMARY CARE. , 2014, 10, P736-P737.		1
151	In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 921-931.	3.3	71
152	Low background and high contrast PET imaging of amyloid- β^2 with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 580-593.	3.3	16
153	1621 " Depressive symptoms and cognitive functioning in elderly. <i>European Psychiatry</i> , 2013, 28, 1.	0.1	0
154	Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. <i>Journal of Neurology</i> , 2013, 260, 1859-1865.	1.8	35
155	Investigating medical decision-making capacity in patients with cognitive impairment using a protocol based on linguistic features. <i>Scandinavian Journal of Psychology</i> , 2013, 54, 386-392.	0.8	13
156	The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. <i>European Heart Journal</i> , 2013, 34, 2585-2591.	1.0	140
157	Association between EEG Abnormalities and CSF Biomarkers in a Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 319-328.	0.7	26
158	Differences in Drug Therapy between Dementia Disorders in the Swedish Dementia Registry: A Nationwide Study of over 7,000 Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 239-248.	0.7	51
159	Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 1039-1044.	1.3	33
160	Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid- β^2 by Human Microglia and Decrease Inflammatory Markers. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 697-713.	1.2	190
161	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 927.	1.0	33
162	Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. <i>Journal of Neurology</i> , 1994, 242, S12-S15.	1.8	44

#	ARTICLE	IF	CITATIONS
163	The nerve growth factor receptor gene is expressed in both neuronal and non-neuronal tissues in the human fetus. <i>International Journal of Developmental Neuroscience</i> , 1991, 9, 57-66.	0.7	40
164	Spatial distributions of cytoskeletal proteins and the nerve growth factor receptor in septal transplants in oculo: Protection from abnormal immunoreactivity by hippocampal co-grafts. <i>Neuroscience</i> , 1991, 44, 381-392.	1.1	7
165	Structural and neurochemical effects in mouse cerebellum following neonatal methylazoxymethanol and 6-hydroxydopamine treatment. <i>International Journal of Developmental Neuroscience</i> , 1990, 8, 107-118.	0.7	12
166	Testicular atrophy and loss of nerve growth factor-immunoreactive germ cell line in rats exposed to n-hexane and a protective effect of simultaneous exposure to toluene or xylene. <i>Archives of Toxicology</i> , 1989, 63, 296-307.	1.9	45
167	Nerve growth factor can influence growth of cortex cerebri and hippocampus: Evidence from intraocular grafts. <i>Neuroscience</i> , 1989, 30, 755-766.	1.1	23
168	Multiple changes in noradrenergic mechanisms in the coeruleo-hippocampal pathway during aging. Structural and functional correlates in intraocular double grafts. <i>Neurobiology of Aging</i> , 1989, 10, 117-124.	1.5	20
169	Growth of brain tissue grafts is dependent upon host age. <i>Mechanisms of Ageing and Development</i> , 1989, 49, 1-22.	2.2	15
170	Age-related alterations in noradrenergic input to the hippocampal formation: structural and functional studies in intraocular transplants. <i>Brain Research</i> , 1989, 478, 269-280.	1.1	23
171	Morphological and electrophysiological studies of human hippocampal transplants in the anterior eye chamber of athymic nude rats. <i>Experimental Neurology</i> , 1989, 104, 162-171.	2.0	21
172	Toluene exposure during maturation of intraocular brain tissue transplants: Alterations of host and graft cerebellar Purkinje neuron function and sensitivity to norepinephrine. <i>Toxicology and Applied Pharmacology</i> , 1988, 96, 296-304.	1.3	6
173	Age-related changes in cerebellar noradrenergic pre- and postsynaptic mechanisms: intrinsic vs extrinsic determinants evaluated with brain grafts in oculo. <i>Brain Research</i> , 1987, 423, 71-78.	1.1	26
174	Glutamic acid decarboxylase- and peptide-immunoreactive neurons in cortex cerebri following development in isolation: Evidence of homotypic and disturbed patterns in intraocular grafts. <i>Synapse</i> , 1987, 1, 539-551.	0.6	11
175	Astroglial development in microencephalic rat brain after fetal methylazoxymethanol treatment. <i>International Journal of Developmental Neuroscience</i> , 1986, 4, 353-362.	0.7	13
176	Growth and development of intraocular fetal cortex cerebri grafts in rats of different ages. <i>Developmental Brain Research</i> , 1986, 28, 75-84.	2.1	20
177	Laminin immunohistochemistry: a simple method to visualize and quantitate vascular structures in the mammalian brain. <i>Journal of Neuroscience Methods</i> , 1986, 17, 275-286.	1.3	79